Myelofibrosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}}{{AE}}{{SR}} | {{CMG}}{{AE}}{{SR}}{{Sab}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for myelofibrosis and there is no screening test currently available for the disease. Routine blood work can be used to check the blood cell counts which can further warrant a bone marrow biopsy. | There is insufficient [[evidence]] to recommend routine [[screening]] for [[myelofibrosis]] and there is no [[screening test]] currently available for the [[disease]]. Routine [[blood]] work can be used to check the [[blood cell]] counts which can further warrant a [[bone marrow biopsy]]. | ||
==Screening== | ==Screening== | ||
*There is insufficient evidence to recommend routine screening for myelofibrosis. | *There is insufficient [[evidence]] to recommend routine [[screening]] for [[myelofibrosis]]. | ||
*Blood cell counts can be determined and monitored for any irregularity which can then further warrant a bone marrow biopsy. | *[[Blood cell]] counts can be determined and monitored for any irregularity which can then further warrant a [[bone marrow biopsy]]. | ||
*According to 2008 WHO classification of myeloproliferative neoplasms, JAK2<sup>V617F</sup> is the most prevalent mutation with approximately 60% of the primary myelofibrosis (PMF) patients carrying this | *According to 2008 [[World Health Organization|World Health Organization (WHO)]] classification of [[Myeloproliferative neoplasm|myeloproliferative neoplasms]], JAK2<sup>V617F</sup> is the most [[Prevalence|prevalent]] [[mutation]] with approximately 60% of the [[Primary myelofibrosis|primary myelofibrosis (PMF)]] [[Patient|patients]] carrying this [[mutation]]. This trend is followed in frequency by the [[Mutation|mutations]] in [[Myeloproliferative leukemia virus oncogene|myeloproliferative leukemia virus (MPL)]] and [[Calreticulin|calreticulin (CALR)]] [[Gene|genes]].<ref name="pmid29426921">{{cite journal |vauthors=Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A |title=The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion |journal=Blood Cancer J |volume=8 |issue=2 |pages=15 |date=February 2018 |pmid=29426921 |pmc=5807384 |doi=10.1038/s41408-018-0054-y |url=}}</ref><ref name="pmid15858187">{{cite journal |vauthors=Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC |title=A gain-of-function mutation of JAK2 in myeloproliferative disorders |journal=N. Engl. J. Med. |volume=352 |issue=17 |pages=1779–90 |date=April 2005 |pmid=15858187 |doi=10.1056/NEJMoa051113 |url=}}</ref><ref name="pmid19357394">{{cite journal |vauthors=Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD |title=The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes |journal=Blood |volume=114 |issue=5 |pages=937–51 |date=July 2009 |pmid=19357394 |doi=10.1182/blood-2009-03-209262 |url=}}</ref> | ||
*Patients can be screened for the above mentioned mutations based on this data. | *[[Patient|Patients]] can be [[Screening|screened]] for the above mentioned [[Mutation|mutations]] based on this data. | ||
==References== | ==References== | ||
Latest revision as of 20:55, 18 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis screening On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis screening |
|
Risk calculators and risk factors for Myelofibrosis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]
Overview
There is insufficient evidence to recommend routine screening for myelofibrosis and there is no screening test currently available for the disease. Routine blood work can be used to check the blood cell counts which can further warrant a bone marrow biopsy.
Screening
- There is insufficient evidence to recommend routine screening for myelofibrosis.
- Blood cell counts can be determined and monitored for any irregularity which can then further warrant a bone marrow biopsy.
- According to 2008 World Health Organization (WHO) classification of myeloproliferative neoplasms, JAK2V617F is the most prevalent mutation with approximately 60% of the primary myelofibrosis (PMF) patients carrying this mutation. This trend is followed in frequency by the mutations in myeloproliferative leukemia virus (MPL) and calreticulin (CALR) genes.[1][2][3]
- Patients can be screened for the above mentioned mutations based on this data.
References
- ↑ Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (February 2018). "The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion". Blood Cancer J. 8 (2): 15. doi:10.1038/s41408-018-0054-y. PMC 5807384. PMID 29426921.
- ↑ Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (April 2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N. Engl. J. Med. 352 (17): 1779–90. doi:10.1056/NEJMoa051113. PMID 15858187.
- ↑ Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (July 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937–51. doi:10.1182/blood-2009-03-209262. PMID 19357394.